Q. T. Ostrom, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, Neuro-Oncol, vol.17, pp.1-62, 2008.

, Input of molecular analysis in medical management of primary brain tumor patients-ClinicalKey, p.22, 2017.

M. Forsting, Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns, AJNR Am. J. Neuroradiol, vol.14, pp.77-87, 1993.

R. Stupp, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med, vol.352, pp.987-996, 2005.

R. Stupp, High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.25, pp.93-101, 2014.

J. Perry, A. Chambers, K. Spithoff, and N. Laperriere, Gliadel wafers in the treatment of malignant glioma: a systematic review, Curr. Oncol, vol.14, pp.189-194, 2007.

A. J. Kumar, Malignant gliomas: MR imaging spectrum of radiation therapyand chemotherapy-induced necrosis of the brain after treatment, Radiology, vol.217, pp.377-384, 2000.

M. M. Husain and J. H. Garcia, Cerebral 'radiation necrosis': vascular and glial features, Acta Neuropathol. (Berl.), vol.36, pp.381-385, 1976.

Y. P. Ramirez, J. L. Weatherbee, R. T. Wheelhouse, and A. H. Ross, Glioblastoma multiforme therapy and mechanisms of resistance, Pharm. Basel Switz, vol.6, pp.1475-1506, 2013.

E. T. Wong, Bevacizumab for recurrent glioblastoma multiforme: a metaanalysis, J. Natl. Compr. Cancer Netw. JNCCN, vol.9, pp.403-407, 2011.

R. Guillevin, C. Menuel, and J. N. Vallée,

, Rev. Neurol, vol.167, pp.704-714, 2011.

J. E. Marks and J. Wong, The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study, Prog. Exp. Tumor Res, vol.29, pp.210-218, 1985.

J. D. Ruben, Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy, Int. J. Radiat. Oncol. Biol. Phys, vol.65, pp.499-508, 2006.

A. W. Lee, Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time, Int. J. Radiat. Oncol. Biol. Phys, vol.53, pp.75-85, 2002.

G. Minniti, Single-Fraction Versus Multifraction (3 × 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis, Int. J. Radiat. Oncol. Biol. Phys, vol.95, pp.1142-1148, 2016.

A. Fabi, Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice, Anticancer Res, vol.29, pp.2607-2610, 2009.

S. Yonezawa, Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis, J. Neurooncol, vol.119, pp.101-109, 2014.

A. L. Stockham, Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery, J. Neurooncol, vol.109, pp.149-158, 2012.

J. Darcourt, 18F-FDOPA PET for the diagnosis of parkinsonian syndromes, Q. J. Nucl. Med. Mol. Imaging Off. Publ. Ital. Assoc. Nucl. Med. AIMN Int. Assoc. Radiopharmacol. IAR Sect. Soc. Of, vol.58, pp.355-365, 2014.

S. Chondrogiannis, Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging, Nucl. Med. Commun, vol.34, pp.1141-1149, 2013.

F. Calabria, A. Chiaravalloti, B. Di-pietro, C. Grasso, and O. Schillaci, Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT, Nucl. Med. Commun, vol.33, pp.563-570, 2012.

A. Becherer, Brain tumour imaging with PET: a comparison between, vol.18

F. and ;. Methionine, Eur. J. Nucl. Med. Mol. Imaging, vol.30, pp.1561-1567, 2003.

A. Grosu, Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas, Int. J. Radiat. Oncol. Biol. Phys, vol.54, pp.842-854, 2002.

S. Karunanithi, Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma, Eur. Radiol, vol.23, pp.2628-2635, 2013.

M. E. Mullins, Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis, AJNR Am. J. Neuroradiol, vol.26, pp.1967-1972, 2005.

E. Karavaeva, Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas, Mol. Imaging Biol. MIB Off. Publ. Acad. Mol. Imaging, vol.17, pp.434-442, 2015.

A. Raimbault, Radionecrosis of malignant glioma and cerebral metastasis: a diagnostic challenge in MRI, Diagn. Interv. Imaging, vol.95, pp.985-1000, 2014.

F. Cicone, Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI, Eur. J. Nucl. Med. Mol. Imaging, vol.42, pp.905-915, 2015.

D. Chiro and G. , Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography, Neurology, vol.32, pp.1323-1329, 1982.

W. Chen, 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.47, pp.904-911, 2006.

S. Karunanithi, Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study, Eur. J. Radiol, vol.83, pp.219-225, 2014.

C. Lapa, Comparison of the amino acid tracers 18F-FET and 18F-DOPA in highgrade glioma patients, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.55, pp.1611-1616, 2014.

C. Kratochwil, Intra-individual comparison of 18 F-FET and 18 F-DOPA in PET imaging of recurrent brain tumors, Neuro-Oncol, vol.16, pp.434-440, 2014.

C. Schiepers, W. Chen, T. Cloughesy, M. Dahlbom, and S. Huang, 18F-FDOPA kinetics in brain tumors, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.48, pp.1651-1661, 2007.

M. González-forero, Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors, Rev. Esp. Med. Nucl, vol.30, pp.88-93, 2011.

G. Pöpperl, FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading, Eur. J. Nucl. Med. Mol. Imaging, vol.34, pp.1933-1942, 2007.

F. Calabria and G. L. Cascini, Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence, Hell. J. Nucl. Med, vol.18, pp.152-156, 2015.

S. Karunanithi, 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT, Eur. J. Nucl. Med. Mol. Imaging, vol.40, pp.1025-1035, 2013.

J. M. Hoffman, The effects of carbidopa administration on 6-[18F]fluoro-Ldopa kinetics in positron emission tomography, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.33, pp.1472-1477, 1992.

K. J. Lizarraga, 18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.55, pp.30-36, 2014.

K. J. Lizarraga, A. A. De-salles, and W. Chen, 18 F-fluorodopa positron-emission tomography: an emerging imaging modality for patients with brain metastases, Expert Rev. Med. Devices, vol.11, pp.327-329, 2014.

B. J. Fueger, Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.51, pp.1532-1538, 2010.

R. S. Youland, The role of LAT1 in (18)F-DOPA uptake in malignant gliomas, J. Neurooncol, vol.111, pp.11-18, 2013.

A. A. Brandes, MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.26, pp.2192-2197, 2008.

K. Herrmann, Comparison of visual and semiquantitative analysis of 18FFDOPA-PET/CT for recurrence detection in glioblastoma patients, Neuro-Oncol, vol.16, pp.603-609, 2014.

M. Dufour, Correlations between 18F-DOPA PET and LAT1 expression for the diagnosis of brain tumour recurrence versus radiation necrosis. EANM 2014 Gotehenburg, Eur J Nucl Med Mol Imaging, vol.41, issue.2, p.312, 2014.

B. Dadone-montaudié, 18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs

, Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses; que je sois déshonoré et méprisé si j'y manque